News

Square Pharma’s Q3 profit slips slightly despite revenue growth
30 Apr 2026
Source: The Business Standard

Square Pharmaceuticals PLC reported a slight decline in profit in the January–March quarter of FY26, despite posting steady revenue growth during the period.

According to the company's latest financial disclosure, consolidated revenue rose 8% year-on-year to Tk2,170.37 crore in the third quarter. However, consolidated net profit slipped 1.40% to Tk596.64 crore, indicating mild pressure on earnings. Consequently, earnings per share (EPS) stood at Tk6.73, down from Tk6.83 in the same quarter of the previous year.

Despite the modest quarterly dip, the company delivered strong performance over the nine-month period from July to March of FY2026. Consolidated revenue increased 13% to Tk6,508 crore, while net profit grew 10% to Tk2,064 crore. EPS for the period rose to Tk23.29, compared to Tk21.15 in the corresponding period of the previous fiscal year.

The unaudited financial statements for the third quarter were approved at a board meeting held today (29 April).

The marginal decline in quarterly profit, despite higher revenue, points to possible increases in operational costs or margin pressures, though the company did not provide detailed explanations. Nevertheless, the overall nine-month results highlight resilience in earnings growth, supported by sustained demand and operational efficiency.

 
About Us

At LankaBangla Securities PLC., we specialize in developing the country's most efficient stock brokerage workforce with unmatched skills and consummate perfectionism. Also, whichever corner of Bangladesh you are in, we have got you covered as you can find our branches and booths spread in the leading cities and towns countrywide.

Market
LBSL Logo
Important Links
HAVE A QUESTION?
© 2019 Copyright: LankaBangla Information System Terms and Conditions